COVID-19 Archive:ワクチン｜株式会社Smart119｜新型コロナウィルス感染症関連論文アーカイブ

Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers (JAMA 2021.5.6)

2021.05.10

US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021 (JAMA 2021.4.30)

2021.04.26

Acute Allergic Reactions to mRNA COVID-19 Vaccines (JAMA 2021.3.8)

2021.04.15

Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination (NEJM 2021.4.9)

2021.04.15

SARS-CoV-2-Specific Antibodies in Breast Milk After COVID-19 Vaccination of Breastfeeding Women (JAMA 2021.4.12)

2021.04.12

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination (NEJM 2021.4.9)

2021.04.06

SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera (Cell 2021.3.20)

2021.03.16

Covid-19 Vaccine Resource Center(NEJM 2021.4.2)②

2021.03.16

Covid-19 Vaccine Resource Center （NEJM 2021.4.2)①

2021.03.05

Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2 (JAMA 2021.3.3)

2021.03.02

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting (NEJM 2021.2.24)

2021.03.02

The Johnson & Johnson Vaccine for COVID-19 (JAMA 2021.3.1)

2021.02.24

How soon will COVID-19 vaccines return life to normal? (Science 2021.2.16)

2021.02.15

Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US--December 14, 2020-January 18, 2021(JAMA 2021.2.12)

2021.02.05

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine (N Eng J Med 2021.2.4)

2020.10.28

What Is Herd Immunity? (JAMA 2020.10.19)

2020.10.02

COVID-19 Archive: ワクチン

Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2 (Nature 2021.6.30)

Adjunct Immune Globulin for Vaccine-Induced Thrombotic Thrombocytopenia (NEJM 2021.6.9)

BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants (NEJM 2021.5.12)

Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers (JAMA 2021.5.6)

US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021 (JAMA 2021.4.30)

Acute Allergic Reactions to mRNA COVID-19 Vaccines (JAMA 2021.3.8)

Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination (NEJM 2021.4.9)

SARS-CoV-2-Specific Antibodies in Breast Milk After COVID-19 Vaccination of Breastfeeding Women (JAMA 2021.4.12)

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination (NEJM 2021.4.9)

SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera (Cell 2021.3.20)

Covid-19 Vaccine Resource Center(NEJM 2021.4.2)②

Covid-19 Vaccine Resource Center （NEJM 2021.4.2)①

Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2 (JAMA 2021.3.3)

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting (NEJM 2021.2.24)

The Johnson & Johnson Vaccine for COVID-19 (JAMA 2021.3.1)

How soon will COVID-19 vaccines return life to normal? (Science 2021.2.16)

Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US--December 14, 2020-January 18, 2021(JAMA 2021.2.12)

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine (N Eng J Med 2021.2.4)

What Is Herd Immunity? (JAMA 2020.10.19)

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults (N Eng J Med 2020.09.29)